Comparison of copper-67- and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors

Journal of Nuclear Medicine

Volumn 38, Issue 6, 1997, Pages 847-853

  Delaloye, Angelika Bischof ^a   Delaloye, Bernard ^b   Buchegger, Franz ^b   Vogel, Charles André ^b   Gillet, Michel ^b   Mach, Jean Pierre ^b   Smith, Alan ^b   Schubiger, P August ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b NONE

Author keywords

Anti CEA; Colorectal carcinoma; Copper 67; Iodine 125; Monoclonal antibodies; Radioimmunotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIBODY; COPPER 67; IODINE 125; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLORECTAL TUMOR; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG TOLERABILITY; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

AGED; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; COPPER RADIOISOTOPES; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION;

EID: 0030992552     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Carrasquillo JA, Krohn KA, Beaumier P, et al. Diagnosis of and therapy for solid tumors with radioiabeled antibodies and immune fragments. Cancer Treat Rep 1984;68:317-328.
2. Delaloye B, Bischof Delaloye A, Pettavel J, et al. Intra-arterial administration of 131-I-anti-CEA-MAb as a therapeutic approach to liver metastases [Abstract]. Nuklearmedizin 1987;26:52.
3. Stewart JS, Hird V, Sullivan M, Snook D, Epenefos AA. Intraperitoneal radioimmu-notherapy for ovarian cancer. Br J Obstet Gynecol 1989;96:529-536.
4. 131I-Lym-1. Cancer Rex 1990;50: 1014-1016.
5. Bischof Delaloye A, Delaloye B. Radioimmunotherapy. In: Munz DL, Emrich D, eds. Immunoscintigraphy. Facts and fiction. Amsterdam: Excerpta Medica; 1990.
6. Meredith RF, Khazaeli MB, Liu T, et al. Dose fractionation of radioiabeled antibodies in patients with metastatic colon cancer. J Nucl Med 1992;33:1648-1653.
7. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-465.
8. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-1224.
9. Czuczman MS, Strauss DJ, Divgi CR, et al. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J Clin Oncol 1993;11:2021-2029.
10. 131I-CC49 in colorectal cancer. Cancer 1994;73(suppl):1057-1066.
11. Welt S, Divgi CR, Kemeny N, et al. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1994;12:1561-1571.
12. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 1986;27:1490-1497.
13. 2) and Fab fragments by imaging tumour xenografts. Eur J Nucl Med 1988;13:598-604.
14. Reilly RM. Radioimmunotherapy of malignancies. Clin Pharm 1991;10:359-375.
15. Moi MK, Meares CF, McCall MJ, Cole WC, DeNardo SJ. Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. Anal Biochem 1985;148:249-253.
16. Kukis DL, Diril H, Greiner DP, et al. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer 1994;73: 779-786.
17. 67Cu-labeled intact and fragmented anti-colon carcinoma monoclonal antibody MAb35. Cancer Res 1993;53:5727-5733.
18. 131I-labeled forms of monoclonal antibodies SEN7 and SWA20 directed against small-cell lung cancer. Int J Cancer 1994;8(suppl):43-48.
19. Deshpande SV, DeNardo SJ, Meares CF, et al. Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice. J Nucl Med 1988;29:217-225.
20. DeNardo G, DeNardo S, Kukis D, Diril H, Suey C, Meares C. Strategies for enhancement of radioimmunotherapy. Nucl Med Biol 1991;18:633-640.
21. 2 fragments from monoclonal anti-carcinoembryonic antigen antibodies. J Clin Invest 1986;77:302-311.
22. Bischof Delaloye A, Delaloye B, Buchegger F, et al. Clinical value of immunoscintigraphy in colorectal carcinoma patients: a prospective study. J Nucl Med 1989;30: 1646-1656.
23. 67Cu from irradiated zinc for use in antibody labeling: a comparison of methods. Appl Radiat Isot 1995;46:329-336.
24. 2+. Helv Chim Acta 1986;69;2081-2086.
25. Smith-Jones PM, Fridrich R, Kaden TA, et al. Antibody labeling with Copper-67 using the bifunctional macrocycle 4-[(1,4,8,11-Tetraazacyclotetradec-1-yl)methyl] benzoic acid. Bioconj Chem 1991;2:415-421.
26. Buchegger F, Mach JP, Pèlegrin A, et al. Radiolabeled chimeric anti-CEA monoclonal antibody compared with the original mouse monoclonal antibody for surgically treated colorectal carcinoma. J Nucl Med 1995;35:420-429.
27. Shen S, DeNardo GL, DeNardo SJ, et al. Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy. J Nucl Med 1996;37:146-149.
28. Anderson CJ, Connett JM, Schwarz SW, et al. Copper-64-labeled antibodies for PET imaging. J Nucl Med 1992;33:1685-1691.
29. Philpott GW, Schwarz SW, Anderson CJ, et al. RadioimmunoPET: Detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J Nucl Med 1995;36:1818-1824.
30. Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease. Medicine 1992;71:139-164.
31. Goodwin DA. Tumor pretargeting [Editorial]. J Nucl Med 1995;36:876-879.
32. Howell RW, Rao DV, Sastry KS. Macroscopic dosimetry for radioimmunotherapy: nonuniform activity distribution in solid tumors. Med Phys 1989;16:66-74.
33. Langmuir VK. Radioimmunotherapy. Clinical results and dosimetric consideralions. Nucl Med Biol 1992;19:213-225.
34. O'Donoghue JA, Bardiès M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995;36:1902-1909.
35. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-326.